Oxytocin is a nine-amino-acid peptide hormone and an FDA-approved prescription drug used in labor and after birth. This guide covers its structure, mechanism, approved uses, key trials, label side effects and status, checked on November 17, 2026.
Quick answer: Oxytocin is a peptide hormone of the posterior pituitary, and synthetic oxytocin is a prescription drug. The Pitocin label lists approved uses before and after delivery. Oxytocin is also studied in people for other purposes. The largest autism trial we reviewed found no benefit over placebo.
Vitrapep does not sell oxytocin; this page is a reference summary of published research and regulatory information. It is not medical advice.
What is oxytocin?
Oxytocin is a short chain of nine amino acids, part of which closes into a ring. PubChem, citing ChEBI, describes it as “a cyclic nonapeptide hormone” with the sequence CYIQNCPLG (PubChem CID 439302). ChEBI calls it the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary. It also acts as a neurotransmitter in the brain.
The Pitocin label describes its active ingredient as synthetic oxytocin (DailyMed). See also our pages on peptide hormones and types of peptides.
Drugs@FDA lists an older application, Syntocinon (NDA 012285), now discontinued and shown without a date. The earliest dated oxytocin record is a Fresenius Kabi application (NDA 018248), approved July 9, 1980.
Oxytocin: key facts
| Fact | Detail |
|---|---|
| Structure | Cyclic peptide of nine amino acids, sequence CYIQNCPLG |
| Class | Peptide hormone of the posterior pituitary; oxytocic agent |
| Molecular formula | C43H66N12O12S2 |
| Molecular weight | 1007.2 g/mol (PubChem) |
| First FDA approval | Earliest dated record: July 9, 1980 (NDA 018248); Pitocin: November 19, 1980 |
| Approved brands | Pitocin; unbranded oxytocin (Fresenius Kabi); Syntocinon (discontinued) |
How does oxytocin work?
The Pitocin label explains the uterine effect. Uterine muscle contracts through the protein actomyosin, under control of a calcium-dependent enzyme. Oxytocin promotes contractions by raising calcium inside the muscle cells. The uterus carries specific oxytocin receptors, and their number rises greatly during pregnancy. It peaks in early labor at term.
Oxytocin also has “inherent pressor and antidiuretic properties,” the label says. It links these to oxytocin’s likeness to vasopressin, since the two differ in only two amino acids. The label gives a plasma half-life of about 1 to 6 minutes. The kidney and liver remove most of it. Our page on peptide half-life explains the term.
A 2018 review describes the oxytocin receptor as a G protein-coupled receptor that can bind Gαi or Gαq proteins (Jurek and Neumann, 2018). It activates pathways such as MAPK, PKC, PLC and CaMK. Drawing on animal and human studies, the review covers roles in maternal behavior, pair bonding, anxiety, trust and sociability.
What is oxytocin approved for?
Drugs@FDA records the original approval of Pitocin, NDA 018261, on November 19, 1980. The current Pitocin label sorts its indications into two groups.
- Antepartum: “the initiation or improvement of uterine contractions,” where suitable for fetal or maternal reasons, to achieve vaginal delivery.
- This covers induction of labor with a medical indication, such as Rh problems, maternal diabetes, preeclampsia or prematurely ruptured membranes.
- It also covers stimulation of labor, as in selected cases of uterine inertia, and adjunctive therapy in incomplete or inevitable abortion.
- Postpartum: “to produce uterine contractions during the third stage of labor and to control postpartum bleeding or hemorrhage.”
An Important Notice in the label defines elective induction as starting labor with no medical indication. The label says the available data are inadequate to weigh benefits against risks. So “Pitocin is not indicated for elective induction of labor.”
What did the key trials of oxytocin show?
The Pitocin label does not describe pivotal trials. Two large randomized human trials help frame oxytocin today, one within its approved uses and one outside them.
CHAMPION (2018). This World Health Organization trial compared heat-stable carbetocin, a related drug, with oxytocin to prevent bleeding after vaginal birth (Widmer et al., 2018). It was double-blind and enrolled 29,645 women in 10 countries. Blood loss of at least 500 mL or use of extra uterotonic drugs occurred in 14.5% with carbetocin and 14.4% with oxytocin. The relative risk was 1.01 (95% CI 0.95 to 1.06), meeting the noninferiority test. For blood loss of at least 1,000 mL, noninferiority was not shown, which the authors linked to low event rates. The trial is registered as ACTRN12614000870651 and has no NCT number.
SOARS-B (2021). This trial tested oxytocin against placebo in 290 children and adolescents, aged 3 to 17, with autism spectrum disorder (NCT01944046). Autism is not an approved use. Over 24 weeks, a social withdrawal score improved by 3.7 points with oxytocin and 3.5 with placebo (P = 0.61). Secondary outcomes generally showed no difference, and adverse events were similar (Sikich et al., 2021). Both trials report human data.
What side effects does the oxytocin label list?
The Pitocin label lists adverse reactions reported in the mother and in the fetus or newborn, without rates.
- Mother: anaphylactic reaction, nausea, vomiting, hypertensive episodes, cardiac arrhythmia, postpartum hemorrhage, pelvic hematoma and rupture of the uterus.
- Mother, also listed: premature ventricular contractions, subarachnoid hemorrhage and fatal afibrinogenemia.
- Fetus or newborn: bradycardia, arrhythmias, low Apgar scores at five minutes, neonatal jaundice and neonatal retinal hemorrhage.
- Fetus or newborn, also listed: permanent CNS or brain damage, fetal death and neonatal seizures.
The label also warns of uterine hypertonicity, spasm and tetanic contraction. Because oxytocin has an intrinsic antidiuretic effect, it warns about water intoxication. It reports severe cases with convulsions and coma, and maternal deaths. The current label on DailyMed has no section titled Boxed Warning. Its Important Notice is the elective induction statement above.
What is the regulatory status of oxytocin, and is it used in research?
Oxytocin is a prescription drug. Drugs@FDA lists Pitocin and the Fresenius Kabi product with prescription status. FDA’s Drug Safety Communications page, current as of November 9, 2026, covers January 2020 onward. None of its titles names oxytocin.
WADA’s 2026 Prohibited List does not name oxytocin. It does name desmopressin, under section S5. Our guide to peptides on the 2026 WADA list covers the sections.
Oxytocin is also a research subject beyond the delivery room. The 2018 review gathers animal and human studies of its receptor, signaling and behavior. SOARS-B shows that work reaching a clinical trial, with a null result. Research findings outside the label are not approved uses.
Frequently asked questions about oxytocin
Is oxytocin a peptide?
Yes. It is a cyclic peptide of nine amino acids, classed as a peptide hormone. Our page on what peptides are gives background.
Is oxytocin the same as Pitocin?
Pitocin is a brand of synthetic oxytocin. Drugs@FDA also lists an unbranded oxytocin product from Fresenius Kabi.
How is oxytocin related to vasopressin?
The Pitocin label says the two hormones differ in only two amino acids. It links oxytocin’s pressor and antidiuretic properties to that likeness.
Is oxytocin approved for autism?
No. Its approved uses are obstetric. In the SOARS-B trial, oxytocin did not beat placebo on social withdrawal scores.
Is oxytocin banned in sport?
WADA’s 2026 Prohibited List does not name it. Athletes should check with their anti-doping organization.
What to know now
- Structure: cyclic nonapeptide, C43H66N12O12S2, 1007.2 g/mol.
- Approval: Pitocin, original approval November 19, 1980, per Drugs@FDA.
- Approved uses: medically indicated labor induction and stimulation, incomplete or inevitable abortion, and postpartum bleeding control.
- Not indicated: elective induction of labor.
- Safety: the label lists uterine rupture, water intoxication and fetal or newborn harms, without rates.
- Research: a 290-child autism trial found no benefit over placebo.
What we’re watching
Two recruiting Phase 3 trials sit within oxytocin’s approved uses. University Hospital, Tours, compares oxytocin with prostaglandins for labor induction after 24 hours of cervical ripening (NCT04949633). It plans 1,494 participants, with primary completion listed for September 2027. Stony Brook University compares misoprostol plus oxytocin with oxytocin alone to prevent early postpartum hemorrhage (NCT05245227). Its primary completion is listed for January 1, 2027. We also watch for Pitocin label updates and WADA’s next Prohibited List.